Polyrizon Ltd. Ordinary Shares PLRZ 深 沪
已收盘 12-19 16:00:00 美东时间
9.43
-0.680
-6.73%
华盛通- 最 高10.20
- 今 开10.09
- 成交量 10.77万股
- 最 低 9.15
- 昨 收 10.11
- 总市值 982.32万
- 52周最高 4200.00
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 2.88
- 委 比 -80.62%
- 总股本 104.17万
- 历史最高 7200.00
- 量 比 0.66
- 振 幅 10.39%
- 历史最低 4.80
- 每 手 1
- 风险率 882.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Polyrizon Submits Pre-RFD To FDA For Its PL-16 Viral Blocker Designed To Reduce Exposure To Influenza And Cold Viruses
The PL-16 Viral Blocker has shown over 90% success in protection of cells against virusesRaanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal
12-19 21:23
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 28.9% to $1.22 during Friday's pre-mar...
12-05 20:05
Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray
Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.
12-05 02:45
Why American Eagle Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of American Eagle Outfitters Inc (NYSE:AEO) rose sharply in pre-market t...
12-03 17:51
Polyrizon Completes Manufacturing Upscaling Milestone For Its Proprietary Nasal-Spray Product Platform
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced the successful
12-02 20:57
Polyrizon shares are trading lower after the company announced a 1-for-6 reverse stock split.
Polyrizon shares are trading lower after the company announced a 1-for-6 revers...
11-26 02:32
Polyrizon Announces Positive In-Vitro Results For Its PL-16 Viral Blocker Candidate Against H1N1 Influenza
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced positive in-vitro
11-06 21:58
Polyrizon Releases Pre-Clinical Results For Its PL-14 Allergy Blocker Showing That PL-14 Effectively Blocked The Penetration Of Der P 1, A Major House Dust Mite Allergen
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced encouraging results
10-06 20:24
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd. announced positive results from a pre-clinical study demonstrating the effectiveness of its PL-14 Allergy Blocker in preventing household dust mite allergen (Der p 1) penetration. After one hour, only 1.07% of the allergen passed through, with minimal penetration at two hours (1.14%) and 13.6% after four hours. The study used allergen loads tens of times higher than typical real-world exposure, suggesting strong protection. The All...
10-06 12:21
